Cancer Vaccine Institute's International Symposium on Immunotherapy
Symposium - London, United Kingdom
Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.
New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.
The Cancer Vaccine Institute’s 1st International Symposium on Immunotherapy will be held at The Royal Society in London on Friday 11 – Saturday 12 October 2013, with an ice-breaker drinks reception on the evening of Thursday 10th October 2013.
This important two day symposium will unite 300 clinicians and researchers to explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.
Organization: Canver Vaccine Institute
(Courtesy of the Royal Society, via en.wikipedia.org)
Cancer Vaccine Institute's International Symposium on Immunotherapy
Fri, Oct 11, 2013 - Sat, Oct 12, 2013
The Royal Society
6 Carlton House Terrace, Piccadilly, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
